Diagnostic Imaging’s Weekly Scan: June 14 — June 20

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

Emerging research, published in the Radiology journal earlier this week, suggests that deep learning may provide equivalent detection to that of radiologists for pancreatic cancer (PC) on non-contrast and contrast-enhanced CT (CECT) and significantly better detection for smaller pancreatic cancers.

In a recent episode of our Molecular Imaging in Focus series, Michael Hofman, MBBS, FRACP, discussed the potential of an emerging PET radiotracer for DVT detection spotlighted in SNMMI’s “Image of the Year,” a new advance in total body PET/CT and other highlights from the SNMMI conference.

The FDA approved the low-dose MRI contrast agent gadoquatrane earlier this week. Indicated for the detection and visualization of abnormal vascularity in the central nervous system (CNS) and non-CNS body regions, gadoquatrane provides 60 percent less gadolinium dosing in comparison to other macrocyclic gadolinium (Gd)-based contrast agents (mGBCAs).

In a recent interview with Diagnostic Imaging, Mary L. Bouxsein, PhD, a past president of the American Society for Bone and Mineral Research, discussed challenges with access to dual-energy X-ray absorptiometry (DEXA) screening for osteoporosis, the emergence of biomechanical CT (BCT) and the potential impact of national Medicare coverage of BCT for bone mass measurement.

For patients with advanced melanoma, the melanin-targeted PET radiotracer (¹⁸F)DMPY2 offered superior detection of metastatic foci in the brain and liver in comparison to (¹⁸F)FDG, according to preliminary comparative research presented at the recent SNMMI conference.

Thank you for checking out the latest edition of Diagnostic Imaging’s Weekly Scan.